![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 51, 36300-36304, December 17, 1999
§,
,
,
From the
Department of Biochemistry, Molecular
Biology and Biophysics, University of Minnesota, St. Paul, Minnesota
55108 and the ¶ Kennedy Krieger Research Institute,
Baltimore, Maryland 21205
| |
ABSTRACT |
|---|
|
|
|---|
The primary sequence of the murine fatty acid
transport protein (FATP1) is very similar to the multigene family of
very long chain (C20-C26) acyl-CoA synthetases. To determine if FATP1
is a long chain acyl coenzyme A synthetase, FATP1-Myc/His fusion protein was expressed in COS1 cells, and its enzymatic activity was
analyzed. In addition, mutations were generated in two domains conserved in acyl-CoA synthetases: a 6- amino acid substitution into
the putative active site (amino acids 249-254) generating mutant M1
and a 59-amino acid deletion into a conserved C-terminal domain (amino
acids 464-523) generating mutant M2. Immunolocalization revealed that
the FATP1-Myc/His forms were distributed between the COS1 cell plasma
membrane and intracellular membranes. COS1 cells expressing wild type
FATP1-Myc/His exhibited a 3-fold increase in the ratio of
lignoceroyl-CoA synthetase activity (C24:0) to palmitoyl-CoA synthetase
activity (C16:0), characteristic of very long chain acyl-CoA
synthetases, whereas both mutant M1 and M2 were catalytically inactive.
Detergent-solubilized FATP1-Myc/His was partially purified using
nickel-based affinity chromatography and demonstrated a 10-fold
increase in very long chain acyl-CoA specific activity (C24:0/C16:0).
These results indicate that FATP1 is a very long chain acyl-CoA
synthetase and suggest that a potential mechanism for facilitating
mammalian fatty acid uptake is via esterification coupled influx.
The murine fatty acid transport protein
(FATP1)1 was identified and
cloned by Schaffer and Lodish (1) from a 3T3-L1 adipocyte cDNA
expression library and is localized to the plasma and other membranes
of adipocytes and other target tissues such as brain, skeletal muscle,
heart, and kidney (1). The FATP1 gene is conserved widely in
biology from bacteria to mammals and is one of several putative
transporters of fatty acids (1-4). Factors that control FATP1 gene expression have been investigated by a number of
laboratories and reveal regulation by several effector systems:
up-regulation during preadipocyte differentiation (1, 5) by peroxisome proliferator-activated receptors (6-8) and by fasting (5) and
down-regulation by insulin (9). Despite a growing body of knowledge
relating to the control of FATP1 gene expression, studies on
the FATP1 protein and its mechanistic role in fatty acid uptake have
been limited (10).
FATP1 exhibits broad-based amino acid similarity to a family of very
long chain coenzyme A synthetases but exhibits only limited sequence
similarity to the multigene family of long chain coenzyme A
synthetases. Disruption of Saccharomyces cerevisiae
FAT1, the yeast homologue to mammalian FATP1 (2),
results in decreased fatty acid uptake, a substantial reduction in very
long chain fatty acyl-CoA synthetase activity, and the accumulation of
very long chain fatty acids (11, 12). Moreover, in animal cells, fatty
acid uptake is diminished in cell lines overexpressing FATP1 if either
endogenous ATP levels are depleted or if FATP1 is mutated (S250A) at a
putative covalent AMP binding site (10). Since the mechanism of fatty
acid activation with coenzyme A requires the formation of an
enzyme-adenylate intermediate and uptake is linked to the presence of
the AMP binding site, we hypothesized that FATP1 may be a plasma
membrane very long chain acyl-CoA synthetase.
To test the hypothesis that FATP1 is a plasma membrane very long chain
acyl-CoA synthetase, COS1 cells were transfected with an epitope-tagged
FATP1 cDNA construct. In addition, two mutant forms of FATP1 were
also epitope-tagged and expressed: a 6-amino acid substitution mutation
from amino acids 249-254, which encompasses the putative catalytic
site, and a 59-amino acid deletion within the carboxyl region of the
protein in a domain highly conserved in acyl-CoA synthetases.
Expression was verified by Western analysis, and localization of FATP1
to the plasma membrane and intracellular membranes was confirmed by
immunofluorescence. Enrichment of FATP1 via affinity chromatography
coincided with an increase in very long chain acyl-CoA specific
activity. These results indicate that FATP1 is a very long chain
acyl-CoA synthetase and suggest that fatty acid uptake in mammalian
cells is mediated by esterification-coupled influx, similar to the
mechanism used by bacteria (13, 14).
Construction of FATP1 cDNA Expression Plasmid--
The FATP1
cDNA was a generous gift of Jean Schaffer, Washington University,
St. Louis, MO. A KpnI restriction site was engineered at the
C terminus of FATP1 and used to subclone the coding region into
pcDNA3.1-Myc/His (Invitrogen) to create pFATP1-Myc/His encoding a
FATP1-Myc/His translational fusion protein under control of the
cytomegalovirus promoter. To develop the M1 substitution mutation at
amino acids 249- 254 (TSGTTG), oligonucleotide-directed mutagenesis (5'-ACAATGGCAGCCTTAGGAAGCGCGGCGGCCGCCTCCAGATAGATGTAAAACAGCCGAT-3') was used to introduce a XhoI site and convert the
sequence to LEAAAA. To develop the deletion mutant M2 at amino
acids 464-523, two polymerase chain reaction products corresponding to
the N-terminal and C-terminal sectors were generated using the
following four primers:
N-5': GCATACCATGGGGGCTCCTGGAGCAGGAACA,
N-3': CCGTACTCGAGATCGAAACGCCGCAGAGGGTC,
C-5': CGCCGCTCGAGGTGGAAGCCGTGCTGAGCCGC,
C-3':. CGTAGGATCCCCAGGCTCAGAGTGAGAAGTC.
The resulting polymerase chain reaction products were ligated at
the engineered XhoI site (found at the N-3' end and the
C-5' end) and captured by polymerase chain reaction using the N-5' and C-3' primers. The amplified fragment was subsequently cloned into
pcDNA3.1-Myc/His. Following cloning, the R2G substitution found
embedded within N-5' was corrected to the original wild type arginine
at position 2. All cloning and polymerase chain reaction reactions were
verified by DNA sequencing.
Viral-mediated DNA Transfection in COS1 Cells--
Transfection
of COS1 cells for either immunofluorescence or acyl-CoA synthetase
activity measurements was performed using polylysine-coated
adenovirus-mediated transfection (15). Replication-deficient adenovirus
was polylysine-coated as described by Allgood et al. (15)
and stored at Indirect Immunofluorescence of FATP-Myc/His in Transfected COS1
Cells--
COS1 cells were plated on 13-mm coverslips (1.6 × 105 cells/coverslip). Twenty-four h post-plating, cells
were transfected with 0.5 µg/coverslip of either pFATP1-Myc/His or
pcDNA3.1 Western Blot Analysis--
Protein concentrations (samples with
Triton X-100) were determined by using a bicinchoninic/copper sulfate
protein assay (Sigma) or Bradford analysis and normalized with
reference to a bovine serum albumin standard. SDS-polyacrylamide gel
electrophorsis of samples was followed by transfer of proteins to
polyvinyldifluoride membranes (Millipore). Membranes were blocked in
phosphate-buffered saline containing 0.05% Tween 20 and 10 mg/ml
bovine serum albumin and probed with monoclonal anti-Myc horseradish
peroxidase antibodies (Invitrogen). Blots were developed with enhanced
chemiluminescence (Amersham Pharmacia Biotech).
Affinity Column Enrichment of FATP1--
COS1 cells were
transfected using polylysine-coated adenovirus as described, and
48 h post-transfection cells were harvested by centrifugation and
immediately frozen in liquid nitrogen. The cell pellet was thawed in
Buffer A (25 mM sucrose, 100 mM Tris-HCl, pH
8.0) and subjected to 4 sequential freeze/thaw steps. Triton X-100 was
added to the cell suspension (final concentration 1%), and the mixture
was allowed to stir overnight. The sample was centrifuged (100,000 × g, 4 °C, 60 min), and the supernatant was recovered
and immediately applied in batch to charged nickel affinity resin
(Qiagen) pre-equilibrated in Buffer A containing 1% Triton X-100 for
10 min at 4 °C for 10 min. The resin was pelleted by low speed
centrifugation and washed extensively in Buffer A. The bound protein
was eluted with Buffer A supplemented with imidazole. Fractions were
concentrated by centrifugation (Amicon 10), immediately frozen, and
stored at -70 °C until further analyzed.
Acyl-CoA Synthetase Activity Assay--
Samples were assayed for
palmitoyl-CoA and lignoceroyl-CoA synthetase activity by conversion of
3H-labeled palmitic acid (Amersham Pharmacia Biotech) or
14C-labeled lignoceric acid (American Radiochemicals) into
their CoA derivatives as described previously (11). For solubilization of long chain and very long chain fatty acids, palmitic and lignoceric acids were dried under nitrogen and solubilized in 50 µl of
pFATP1-Myc/His was transfected into COS1 cells using
virus-mediated transfection, and protein expression was verified by
Western analysis utilizing anti-Myc antibodies. FATP1-Myc/His exhibited a relative molecular mass of 73 kDa (Fig.
1), consistent with its predicted mass of
~70 kDa plus the Myc tag and polyhistidine tract. As expected,
nontransfected cells showed no corresponding immune-reactive protein.
There is no detectable endogenous FATP1 in COS1 cells as determined by
Northern blotting of COS1 RNA using a FATP1 probe or by immunoblotting
using a monospecific polyclonal anti-peptide antibody directed toward
amino acids 192-215 of FATP1 (results not shown).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
70 °C until use. For transfection, COS1 cells were
plated in 10-cm plates (1.3 × 106 cells) and grown
overnight at 37 °C. Adenovirus (typically ~200 plaque-forming
units/cell) was incubated with pFATP1-Myc/His (10 µg) at 25 °C in
the dark for 30 min, and the virus/DNA mixture was incubated with
additional polylysine (125-fold molar to DNA) for an additional 30 min.
The virus/DNA/polylysine mixture was delivered to the COS1 cells in
4.0-ml medium, and 2 h post-transfection, additional medium (4.0 ml) supplemented with fetal bovine serum (20%) was added. Forty eight
h post-transfection, cells were harvested for analysis.
-galactosidase-Myc/His (Invitrogen) complexed to
polylysine-coated adenovirus and allowed to grow for an additional
24 h. Cells were then fixed with formaldehyde and glutaraldehyde
in the presence or absence of 0.01% Triton X-100 at 37 °C. After
fixation, the cells were incubated with anti-Myc monoclonal antibodies
(Invitrogen) for 2 h at 37 °C, washed with phosphate-buffered
saline, and then incubated with fluorescein-labeled secondary antibody
(Organon Teknika) for 1 h at 25 °C. Preparations were viewed
using a Nikon Eclipse E800 photomicroscope equipped with brightfield
phase and fluorescence optics including a 100-W mercury lamp
epi-fluorescence illumination with standard fluorescein (excitation
filter 470-490 nm, barrier 520-580 nm) filter sets. Digital images
were collected using a CoolCam liquid-cooled, three-chip color CCD
camera (Cool Camera Company, Decatur, GA) and captured to a 486DX2
personal computer using Image Pro Plus version 3.0 software (Media
Cybernetics, Silver Spring, MD).
-cyclodextrin (10 mg/ml) before use.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (9K):
[in a new window]
Fig. 1.
Western analysis of
pFATP1-Myc/His-transfected COS1 cells. COS1 cells were transfected
with pFATP1-Myc/His as described under "Experimental Procedures,"
and protein extracts were separated by 10% SDS-polyacrylamide gel
electrophorsis. The separated proteins were transferred to a
polyvinyldifluoride membrane and blotted with anti-Myc monoclonal
antibodies. Antigen detection was with enhanced chemiluminescence.
Markers refer to molecular mass in kilodaltons.
To determine the intracellular location of FATP1-Myc/His, immune
localization was performed using anti-Myc monoclonal antibodies. Immunohistochemical analysis of COS1 cells transfected with either pFATP1-Myc/His or with a pcDNA 3.1
-galactosidase-Myc/His
control vector was carried out in the presence and absence of detergent (Fig. 2), as described under
"Experimental Procedures." The outer membrane of COS1 cells
transfected with pFATP1-Myc/His was labeled (Fig. 2, panel
A), indicating the presence of antigen on the cell surface.
Subsequent dispersion of this immunofluorescent signal by detergent, as
shown in the Triton X-100-treated cells (Fig. 2, panel B),
coupled with the labeling in nondisrupted transfected COS1 cells (Fig.
2, panel A) substantiate the presence of some FATP1-Myc/His
in the COS1 plasma membrane. However, as seen in Fig. 2, Triton X-100
treatment also revealed the presence of additional FATP1-Myc/His within
internal membranes. This point demonstrates that FATP1-Myc/His is
distributed broadly within cellular membranes, being present on both
the plasma membrane and intracellular membranes. Cytoplasmically
localized
-galactosidase-Myc/His was not immune-reactive unless the
membranes were disrupted with Triton X-100, verifying the integrity of
the plasma membrane in the absence of detergents (Fig. 2, panels
C and D).
|
To test the hypothesis that FATP1 is a very long chain CoA synthetase,
pFATP1-Myc/His-transfected COS1 cells were assayed for both
palmitoyl-CoA and lignoceroyl-CoA synthetase activities. As shown in
Table I, a 3- to 4-fold increase in
lignoceroyl-CoA synthetase activity was measured in
pFATP1-Myc/His-transfected cells (3.9 ± 0.8 nmol/20 min/mg of
protein) relative to nontransfected virus-treated cells (1.0 ± 0.2 nmol/20 min/mg of protein). Palmitoyl-CoA synthetase activity was
unaffected by FATP1 transfection (Table I). As shown in Table I, a 3- to 4-fold increase in the lignoceroyl-CoA synthetase activity relative
to palmitoyl-CoA synthetase activity was measured for FATP1 transfected
(6.8 ± 0.8) versus nontransfected (2.1 ± 0.1)
cells. To ensure that the expression plasmid itself was not responsible
for the increase in the ratio of C24:0 and C16:0 activities in
transfected COS1 cells, COS1 cells were also transfected with
pcDNA3.1
-galactosidase-Myc/His. The ratio of C24:0 to C16:0
acyl-CoA synthetase activities for both nontransfected COS1 cells and
for COS1 cells transfected with pcDNA3.1
-galactosidase-Myc/His were comparable with virus-treated cells with ratios of 1.9 and 1.5, respectively (as compared with 2.1 for virus treated COS1 cells, Table
I). pFATP1-Myc/His-transfected COS1 cells have an increase in very long
chain but not long chain acyl-CoA synthetase activity. The 3-fold
increase in the specific activity reflected in the C24:0/C16:0 ratio of
pFATP1-Myc/His-transfected cells is characteristic of other documented
very long chain acyl-CoA synthetases (11, 16, 32).
|
Stuhlsatz-Krouper et al. (10) show that substitution of
alanine for serine at position 250 in FATP1 inhibits ATP binding and
reduces fatty acid transport activity. These results suggested that the
domain surrounding amino acid 250, which contains the signature motif
249TSGTTG critical for ATP-dependent ligase
reactions, may be required for synthetase activity. Therefore, we
generated mutant M1, which contains a 6-amino acid substitution at
those positions introducing the sequence 249LEAAAA. Whereas
the motif 1 signature is not diagnostic for acyl-CoA synthetases, a
domain within the C-terminal half of the protein is highly conserved in
the enzymes capable of esterifying either long chain or very long chain
fatty acids (11). We introduced a deletion of this second motif (M2)
into FATP1 (amino acids 464 to 523), producing a protein truncated by
59 amino acids. Mutants M1 and M2 were introduced into COS1 cells via
polylysine-coated adenovirus-mediated transfection, and the level of
heterologous protein expression was assessed by blotting with anti-Myc
antibodies. As shown in Fig. 3, although
all FATP1 forms were similarly expressed, only the wild type FATP1
yielded a substantial increase in C24:0/C16:0 acitivity; both mutant M1
and M2 were devoid of any very long chain acyl-CoA synthetase activity.
This finding is consistent with that of Stuhlsatz-Krouper et
al. (10), who demonstrate that mutation at serine 250 abolished
ATP binding and transport activity. Moreover, analysis of mutant M2
demonstrates that this highly conserved domain, whose function is not
known, is also required for catalytic activity.
|
A positive correlation between FATP1 expression and fatty acid uptake has been previously demonstrated (1, 8, 10, 17). Such internalized fatty acids may act as transcriptional regulators, potentially activating gene expression of a COS1 cell very long chain acyl-CoA synthetase. To ensure that the increase in lignoceroyl-CoA synthetase activity measured in pFATP1-Myc/His-transformed cells was directly due to the enzymatic activity of FATP1-Myc/His and not indirectly due to the fatty acid transport activity of FATP1, the experiment was performed using medium containing delipidated serum. Transfection of C0S1 cells with pFATP1-Myc/His in delipidated medium followed by assay of acyl-CoA synthetase activity resulted in a C24:0/C16:0 specific activity ratio (×100) of 7.3 (results not shown). These results indicate that exogenous fatty acids internalized due to the cell-surface expression of FATP1-Myc/His are not likely up-regulating the expression of an endogenous very long chain acyl-CoA synthetase gene.
To further demonstrate that the lignoceroyl-CoA synthetase activity
associated with pFATP1-Myc/His transformed COS1 cells was directly
attributable to an enzymatic activity intrinsic to FATP1-Myc/His, the
protein was partially purified using chelating Ni+2-affinity chromatography. Total COS1 cell membranes,
solubilized membrane proteins, the wash, and elution column fractions
were assayed for lignoceroyl-CoA and palmitoyl-CoA synthetase activity (Fig. 4). The ratio of the acyl-CoA
synthetase activities (C24:0/C16:0) increased 10-fold in the
FATP-enriched elution column fraction when compared with the starting
solubilized COS1 cell membrane material (Fig. 4). Western blotting of
the various fractions indicated that an increase in FATP1
immunoreactivity paralleled the increase in C24:0/C16:0 specific
activity.
|
| |
DISCUSSION |
|---|
|
|
|---|
Our results characterize the FATP1 gene product as a
very long chain acyl-CoA synthetase. This finding is supported by the C24:0/C16:0 activity measurements in transfected cells and in the
activity of partially purified FATP1-Myc/His protein. The substantial
enrichment of FATP1-Myc/His by nickel-based affinity chromatography
resulted in a 10-fold increase in very long chain acyl-CoA synthetase
specific activity (Fig. 4), supporting the conclusion that FATP1 itself
is responsible for the activity measured in transfected COS1 cells
(Table I). The amino acid sequences of very long chain acyl-CoA
synthetases are overall very similar but are generally characterized by
two domains of very high identity, shown in Fig.
5 as motif 1 and motif 2 (11). Motif 1 is
a covalent AMP binding site common to all acyl-CoA synthetases (long
chain and very long chain) and necessary for formation of the
acyl-adenylate reaction intermediate. Mutagenesis of serine 250 to
alanine within motif 1 results in an FATP1 form with markedly
diminished fatty acid transport activity (10). Our results also
demonstrated that mutation at motif 1 renders the protein catalytically
inactive (Fig. 3). Motif 2, whose function is not known, is unique to
acyl-CoA synthetases and is somewhat diagnostic in distinguishing very long chain acyl-CoA sequences from long chain acyl CoA synthetases in
data base searches (11). Fig. 3 shows that motif 2 is also necessary
for catalytic activity. This is interesting, for a number of folding
algorithms used to predict the topology of membrane proteins such as
FATP1 place a transmembrane domain between motif 1 and motif 2 from
amino acids 294-313. If such topology predictions were proven to be
true, it would suggest that domains on either side of the membrane are
necessary for catalytic activity. It is important to note that the
fatty acid substrate specificity of long chain versus very
long chain acyl-CoA synthetases is not absolute. That is, there are
overlapping substrate specificities for fatty acids of varying carbon
lengths. The use of the ratios of two end points, C24:0 and C16:0,
provides a convenient and technically manageable method for assessing
and describing an enzyme as a long chain or a very long chain acyl-CoA
synthetase. It is likely that the BODIPY 3823-labeled fatty acid analog
used by Schaffer and Lodish (1) is a substrate for both FATP and the
long chain acyl-CoA synthetase, which led to their concurrent identification in the functional screening assay. Experiments are under
way to evaluate this possibility.
|
Several proteins localized to the fat cell plasma membrane have been implicated in fatty acid uptake. Many of these have been characterized by their ability to bind fatty acids or fatty acid derivatives (reviewed in Refs. 3 and 4). In contrast, FATP1 was cloned from a 3T3-L1 adipocyte cDNA library as the product of a functional screen utilizing a BODIPY 3823-labeled fatty acid and a fluorescence-activated cell sorting assay. This screen yielded two different clones; one was FATP1, and the other was the murine long chain acyl-CoA synthetase 1 (1). Transfection of either clone into COS7 cells resulted in a 3-4-fold increase in oleic acid uptake when compared with nontransfected cells. In light of our finding that FATP1 is a very long chain acyl-CoA synthetase, it seems reasonable to suggest that the screening method employed by Schaffer and Lodish (1) identified two metabolic enzymes whose functions in sum are linked to fatty acid uptake for molecules of 12-26 carbons or for fatty acids containing branched chains. Our results do not preclude a role for FATP1 as a fatty acid transporter. However, its amino acid sequence similarity to the very long chain acyl-CoA synthetase multigene family make it more likely that the protein functions in metabolic activation of very long chain fatty acids and not in fatty acid transport per se. Interestingly, recent work by Gargiulo et al. (31) shows that the adipocyte long chain acyl-CoA synthetase is also expressed in part on the plasma membrane, similar to the distribution of FATP1.
Our results do not address the possibility of a fatty acid permease capable of working in conjunction with either the long chain or very long chain acyl-CoA synthetases to mediate fatty acid uptake. Fatty acid uptake may occur by a diffusional (18-22) or protein-mediated (23-25) event followed by esterification of the internalized fatty acid. In general, we refer to this process as esterification-coupled influx. That is, the uptake of fatty acids at the plasma membrane, either via a diffusional or protein-mediated event, is coupled to the ATP-dependent esterification of the lipid, producing the corresponding acyl-CoA. Indeed, Schaffer and co-workers (10) show that in cells expressing the S250A mutant of FATP1 or in cells depleted of ATP, fatty acid uptake is severely compromised, presumably due to an inability to form the acyl-adenylate intermediate. Consistent with this, in Escherichia coli, fatty acids traverse the inner membrane in an ATP-dependent event coupled to esterification catalyzed by the FadD gene product, an acyl-CoA synthetase (14, 26-29). The advantage of the esterification-coupled influx mechanism is that the acyl-CoAs are not able to diffuse back across the plasma membrane, effectively locking the fatty acid in the cell. This process would be considered functionally analogous to phosphorylation of glucose by either hexokinase or glucokinase producing glucose 6-phosphate, thereby preventing its back diffusion from the cell.
In conclusion, we have identified the FATP1 gene product as
a very long chain acyl-CoA synthetase and proposed that fatty acid
uptake occurs via esterification-coupled influx. The available clones
and cell models allow for the testing of this model. In light of these
findings, recent data base analysis of genes predicted to encode fatty
acid transporters (30) in a wide variety of genera may need to be
expanded to include an evolutionary-conserved family of acyl-CoA
synthetases capable of esterifying very long chain or branched chain
fatty acids.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Mark Sanders and David Gartner of the University of Minnesota Imaging Center for their expertise and guidance in preparation and analysis of samples for FATP1-Myc/His immunolocalization. We also thank Stephanie Mihalik for technical advice concerning the acyl-CoA synthetase assay, Jun Liu for preparing adenovirus stocks, and Ann Hertzel for guidance in optimization of adenovirus-mediated transfection.
| |
FOOTNOTES |
|---|
* This work supported by National Institutes of Health Grants DK49807 (to D. A. B.) and HD10981 (to P. W).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ A recipient of a University of Minnesota Graduate School Doctoral Dissertation Fellowship.
To whom correspondence should be addressed: Dept. of
Biochemistry, Molecular Biology and Biophysics, University of
Minnesota, 1479 Gortner Ave., St. Paul, MN 55108. Tel.: 612-624-2712;
Fax: 612-625-5780; E-mail: david-b@biosci.cbs.umn.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: FATP1, murine fatty acid transport protein; Myc/His, the Myc epitope translationally fused to a 6-amino acid polyhistidine tract.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Schaffer, J. E., and Lodish, H. F. (1994) Cell 79, 427-436[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
Faergeman, N. J.,
DiRusso, C. C.,
Elberger, A.,
Knudsen, J.,
and Black, P. N.
(1997)
J. Biol. Chem.
272,
8531-8538 |
| 3. | Hui, T. Y., and Bernlohr, D. A. (1997) Front. Biosci. 2, 222-231 |
| 4. | Bernlohr, D. A, Ribarik Coe, N., and LiCata, V. J. (1999) Semin. Cell Dev. Biol. 10, 43-49[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Man, M. Z., Hui, T. Y., Schaffer, J. E., Lodish, H. F., and Bernlohr, D. A. (1996) Mol. Endocrinol. 10, 1021-1028[Abstract] |
| 6. |
Motojima, K.,
Passily, P.,
Peters, J. M.,
Gonzalez, F. J.,
and Latruffe, N.
(1998)
J. Biol. Chem.
273,
16710-16714 |
| 7. |
Martin, G.,
Schoonjans, K.,
Lefebvre, A. M.,
Staels, B.,
and Auwerx, J.
(1997)
J. Biol. Chem.
272,
28210-28217 |
| 8. |
Frohnert, B. I.,
Hui, T. Y.,
and Bernlohr, D. A.
(1999)
J. Biol. Chem.
274,
3970-3977 |
| 9. |
Hui, T. Y.,
Frohnert, B. I.,
Smith, A. J.,
Schaffer, J. E,
and Bernlohr, D. A.
(1998)
J. Biol. Chem.
273,
27420-27429 |
| 10. |
Stuhlsatz-Krouper, S. M.,
Bennett, N. E.,
and Schaffer, J. E.
(1998)
J. Biol. Chem.
273,
28642-28650 |
| 11. |
Watkins, P. A.,
Lu, J. -F.,
Steinberg, S. J.,
Gould, S. J.,
Smith, K. D.,
and Braiterman, L. T.
(1998)
J. Biol. Chem.
273,
18210-18219 |
| 12. |
Choi, J.-Y.,
and Martin, C. E.
(1999)
J. Biol. Chem.
274,
4671-4683 |
| 13. |
Black, P. N.,
DiRusso, C. C.,
Metzger, A. K.,
and Heimert, T. L.
(1992)
J. Biol. Chem.
267,
25513-25520 |
| 14. | Black, P. N., and DiRusso, C. C. (1994) Biochim. Biophys. Acta 1210, 123-145[Medline] [Order article via Infotrieve] |
| 15. | Allgood, V. E., Zhang, Y., O'Malley, B. W., and Weigel, N. L. (1997) Biochemistry 36, 224-232[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Uchida, Y.,
Kondo, N.,
Orii, T.,
and Hashimoto, T.
(1996)
J. Biochem. (Tokyo)
119,
565-571 |
| 17. |
Berk, P. D.,
Zhou, S. L.,
Kiang, C. L.,
Stump, D.,
Bradbury, M.,
and Isola, L. M.
(1997)
J. Biol. Chem.
272,
8830-8835 |
| 18. | Goswitz, V. C., and Brooker, R. J. (1995) Protein Sci. 4, 534-570[Abstract] |
| 19. | Triggati, B. L., and Gerber, G. E. (1996) Biochem. J. 313, 487-494 |
| 20. | Kamp, F., and Hamilton, J. A. (1993) Biochemistry 32, 11074-11086[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Kamp, F., Zakim, D., Zhang, F., Noy, N., and Hamilton, J. A. (1995) Biochemistry 34, 11928-11937[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Zakim, D. (1996) Proc. Soc. Exp. Biol. Med. 212, 5-14[Medline] [Order article via Infotrieve] |
| 23. |
Abumrad, N. A.,
Park, J. H.,
and Park, C. R.
(1984)
J. Biol. Chem.
259,
8945-8953 |
| 24. | Berk, P. D. (1996) Proc. Soc. Exp. Biol. Med. 212, 1-4[Medline] [Order article via Infotrieve] |
| 25. | Fitscher, B. A., Elsing, C., Riedel, H. -D., Gorski, J., and Stremmel, W. (1996) Proc. Soc. Exp. Biol. Med. 212, 15-23[Medline] [Order article via Infotrieve] |
| 26. |
Black, P. N.,
Zhang, Q.,
Weimar, J. D.,
and DiRusso, C. C.
(1997)
J. Biol. Chem.
272,
4896-4903 |
| 27. | Mangroo, D., and Gerber, G. E. (1993) Biochem. Cell Biol. 71, 51-56[Medline] [Order article via Infotrieve] |
| 28. | Kameda, K. (1986) Biochem. Int. 13, 343-350[Medline] [Order article via Infotrieve] |
| 29. | Kameda, K., Suzuki, L. K., and Imai, Y. (1987) Biochem. Int. 14, 227-234[Medline] [Order article via Infotrieve] |
| 30. |
Hirsh, D.,
Stahl, A.,
and Lodish, H. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8625-8629 |
| 31. |
Gargiulo, C. E.,
Stuhlsatz-Krouper, S. M.,
and Schaffer, J. E.
(1999)
J. Lipid Res.
40,
881-892 |
| 32. | Steinberg, S. J., Wang, S. J., Kemp, S., Kim, D. G., Mihalik, S. J., and Watkins, P. A. (1999) Biochem. Biophys. Res. Commun. 257, 615-621[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
M. E. Rinella, M. S. Elias, R. R. Smolak, T. Fu, J. Borensztajn, and R. M. Green Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet J. Lipid Res., May 1, 2008; 49(5): 1068 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, P. N. Black, A. Chokshi, A. Sandoval-Alvarez, R. Vatsyayan, W. Sealls, and C. C. DiRusso High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias J. Lipid Res., January 1, 2008; 49(1): 230 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jia, C. L. Moulson, Z. Pei, J. H. Miner, and P. A. Watkins Fatty Acid Transport Protein 4 Is the Principal Very Long Chain Fatty Acyl-CoA Synthetase in Skin Fibroblasts J. Biol. Chem., July 13, 2007; 282(28): 20573 - 20583. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Iakoubov, A. Izzo, A. Yeung, C. I. Whiteside, and P. L. Brubaker Protein Kinase C{zeta} Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells Endocrinology, March 1, 2007; 148(3): 1089 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bonen, A. Chabowski, J. J. F. P Luiken, and J. F. C. Glatz Mechanisms and Regulation of Protein-Mediated Cellular Fatty Acid Uptake: Molecular, Biochemical, and Physiological Evidence Physiology, February 1, 2007; 22(1): 15 - 28. [Full Text] [PDF] |
||||
![]() |
K. Milger, T. Herrmann, C. Becker, D. Gotthardt, J. Zickwolf, R. Ehehalt, P. A. Watkins, W. Stremmel, and J. Fullekrug Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4 J. Cell Sci., November 15, 2006; 119(22): 4678 - 4688. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Larque, S. Krauss-Etschmann, C. Campoy, D. Hartl, J. Linde, M. Klingler, H. Demmelmair, A. Cano, A. Gil, B. Bondy, et al. Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 853 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. An and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Doege and A. Stahl Protein-mediated Fatty Acid uptake: novel insights from in vivo models. Physiology, August 1, 2006; 21: 259 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wu, A. M. Ortegon, B. Tsang, H. Doege, K. R. Feingold, and A. Stahl FATP1 Is an Insulin-Sensitive Fatty Acid Transporter Involved in Diet-Induced Obesity. Mol. Cell. Biol., May 1, 2006; 26(9): 3455 - 3467. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Richards, J. D. Harp, D. S. Ory, and J. E. Schaffer Fatty acid transport protein 1 and long-chain acyl coenzyme A synthetase 1 interact in adipocytes J. Lipid Res., March 1, 2006; 47(3): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kiens Skeletal Muscle Lipid Metabolism in Exercise and Insulin Resistance Physiol Rev, January 1, 2006; 86(1): 205 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. M. Coort, W. A. Coumans, A. Bonen, G. J. van der Vusse, J. F. C. Glatz, and J. J. F. P. Luiken Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats J. Lipid Res., June 1, 2005; 46(6): 1295 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. DiRusso, H. Li, D. Darwis, P. A. Watkins, J. Berger, and P. N. Black Comparative Biochemical Studies of the Murine Fatty Acid Transport Proteins (FATP) Expressed in Yeast J. Biol. Chem., April 29, 2005; 280(17): 16829 - 16837. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Hall, B. M. Wiczer, T. Herrmann, W. Stremmel, and D. A. Bernlohr Enzymatic Properties of Purified Murine Fatty Acid Transport Protein 4 and Analysis of Acyl-CoA Synthetase Activities in Tissues from FATP4 Null Mice J. Biol. Chem., March 25, 2005; 280(12): 11948 - 11954. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Marszalek, C. Kitidis, C. C. DiRusso, and H. F. Lodish Long-chain Acyl-CoA Synthetase 6 Preferentially Promotes DHA Metabolism J. Biol. Chem., March 18, 2005; 280(11): 10817 - 10826. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Pei, P. Fraisl, J. Berger, Z. Jia, S. Forss-Petter, and P. A. Watkins Mouse Very Long-chain Acyl-CoA Synthetase 3/Fatty Acid Transport Protein 3 Catalyzes Fatty Acid Activation but Not Fatty Acid Transport in MA-10 Cells J. Biol. Chem., December 24, 2004; 279(52): 54454 - 54462. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Castellani, P. Gargalovic, M. Febbraio, S. Charugundla, M.-L. Jien, and A. J. Lusis Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II J. Lipid Res., December 1, 2004; 45(12): 2377 - 2387. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. DiRusso and P. N. Black Bacterial Long Chain Fatty Acid Transport: Gateway to a Fatty Acid-responsive Signaling System J. Biol. Chem., November 26, 2004; 279(48): 49563 - 49566. [Full Text] [PDF] |
||||
![]() |
D. G. Mashek, K. E. Bornfeldt, R. A. Coleman, J. Berger, D. A. Bernlohr, P. Black, C. C. DiRusso, S. A. Farber, W. Guo, N. Hashimoto, et al. Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family J. Lipid Res., October 1, 2004; 45(10): 1958 - 1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Sauer, R. T. Dauchy, D. E. Blask, J. A. Krause, L. K. Davidson, E. M. Dauchy, K. J. Welham, and K. Coupland Conjugated Linoleic Acid Isomers and Trans Fatty Acids Inhibit Fatty Acid Transport in Hepatoma 7288CTC and Inguinal Fat Pads in Buffalo Rats J. Nutr., August 1, 2004; 134(8): 1989 - 1997. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Y. Koonen, C. R. Benton, Y. Arumugam, N. N. Tandon, J. Calles-Escandon, J. F. C. Glatz, J. J. F. P. Luiken, and A. Bonen Different mechanisms can alter fatty acid transport when muscle contractile activity is chronically altered Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E1042 - E1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. K. Koo, J. B. Ohlrogge, and M. Pollard On the Export of Fatty Acids from the Chloroplast J. Biol. Chem., April 16, 2004; 279(16): 16101 - 16110. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Gertow, M. Bellanda, P. Eriksson, S. Boquist, A. Hamsten, M. Sunnerhagen, and R. M. Fisher Genetic and Structural Evaluation of Fatty Acid Transport Protein-4 in Relation to Markers of the Insulin Resistance Syndrome J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 392 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Gimeno, D. J. Hirsch, S. Punreddy, Y. Sun, A. M. Ortegon, H. Wu, T. Daniels, A. Stricker-Krongrad, H. F. Lodish, and A. Stahl Targeted Deletion of Fatty Acid Transport Protein-4 Results in Early Embryonic Lethality J. Biol. Chem., December 5, 2003; 278(49): 49512 - 49516. [Abstract] [Full Text] [PDF] |